WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced th

The presentations include new data from clinical trials and real-world evidence which reinforce the

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates sig

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting th

PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a

Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and rais

PTC Therapeutics Inc. (NASDAQ:PTCT) on Wednesday said it is expanding its rare disease portfolio thr

PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, w

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical

Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's e

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure migh

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight an

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Conse

PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.

– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenu

Fifth Third Bancorp increased its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 12,

CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm

Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,81

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today th

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweig

The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options

PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs a

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market l

PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimi

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning

Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and ra

TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefit

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohor

Jefferies analyst Faisal Khurshid downgrades PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight an

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight a

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform

B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lo

PTC Therapeutics (NASDAQ:PTCT) sees FY2026 sales of $700.000 million-$800.000 million vs $959.579 mi